Aripiprazole: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett mNo edit summary |
imported>Tom Morris No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
In [[medicine]], '''aripiprazole''' (pronunciation: ay ri pip' ray zole) is an atypical or second generation [[anti-psychotic agent]] that "has both presynaptic [[dopamine]] autoreceptor agonistic activity and postsynaptic D<sub>2</sub> receptor antagonistic activity; structure given in first source; use associated with hyperglycemia."<ref>{{MeSH}}</ref> | In [[medicine]], '''aripiprazole''' (pronunciation: ay ri pip' ray zole) is an atypical or second generation [[anti-psychotic agent]] that "has both presynaptic [[dopamine]] autoreceptor agonistic activity and postsynaptic D<sub>2</sub> receptor antagonistic activity; structure given in first source; use associated with hyperglycemia."<ref>{{MeSH}}</ref> | ||
Revision as of 21:06, 22 August 2010
In medicine, aripiprazole (pronunciation: ay ri pip' ray zole) is an atypical or second generation anti-psychotic agent that "has both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity; structure given in first source; use associated with hyperglycemia."[1]
In the United States, the Food and Drug Administration has approved the use of aripiprazole for the treatment of schizophrenia, bipolar I disorder, major depressive disorder, irritability associated with autistic disorder agitation associated with schizophrenia or mania from bipolar disorder. The trade name is Abilify™. Although not approved for the treatment of dementia, aripiprazole has been studied in this setting.
References
- ↑ Anonymous (2024), Aripiprazole (English). Medical Subject Headings. U.S. National Library of Medicine.